Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SAN ANTONIO, March 01, 2018 -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN brings government, academic and industry leaders together to accelerate the discovery, development and validation of biomarkers for cancer risk and early detection.
“Collaboration with the National Cancer Institute’s Early Detection Research Network is an important step in the development of CyPath© Lung, our non-invasive, early-stage lung cancer test. EDRN also offers valuable resources to advance our promising oncological diagnostics for prostate and bladder cancers,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “EDRN and its members share many of our objectives, including expanding our knowledge of the biology of cancer, developing and testing promising technologies for the early detection of cancer, and promoting collaboration to advance the clinical application of tests like CyPath© Lung.”
bioAffinity Technologies’ Executive Vice President Vivienne Rebel, PhD, MD, and Director of Operations Xavier Reveles, MS GC(ASCP)cm, will attend next week’s 10th EDRN Scientific Workshop from March 6-8, 2018, in Bethesda, MD. The workshop will focus on standards and regulatory science, novel technologies for precision detection, imaging, clinical and validation science, alliances and consortia on biomarkers, and non-profit foundations’ support for biomarkers.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
Contact: Maria Zannes, 505.400.9747
